18302 Irvine Blvd #200, Tustin, CA 92780 (949) 825-7650 prestigemedigroup.com
It attaches to GLP-1 receptors, mimicking the hormone
Side Effects & Safety Typical first-cycle side effects: Weeks 1-2: mild water retention, vivid dreams, light head/warmth after injection Weeks 3-4: occasional joint stiffness, improved sleep quality, slight appetite increase overnight Weeks 5-8: adaptation phase most side effects fade, body composition changes visible Clinical discontinuation signals (trial-reported): Clinical participants in tesamorelin studies were discontinued upon experiencing: Persistent headaches with visual changes (intracranial pressure marker in trial monitoring protocols) Sustained fasting glucose elevation of ~15 mg/dL above baseline Unusual peripheral swelling persisting beyond weeks 1-2 Carpal tunnel symptoms unresponsive to dose titration in community-reported protocols Tesamorelin has been studied at 2mg/day for 6+ months without notable safety signals at therapeutic doses
Large glucose swings, visceral adiposity, fatty liver, and elevated fasting insulin may all signal a metabolic environment that is less favorable for long-term cognitive health
Column Dimensions: 2.1 50100 mm, sub-2 m for high resolution
Instead, OXM treatment resulted in improved glycaemic control at a magnitude comparable with that of a selective GLP-1R agonist [79]
